ULTRAGENYX PHARMACEUTICAL INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -1.10% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -1.10%.
- ULTRAGENYX PHARMACEUTICAL INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.30%.
- ULTRAGENYX PHARMACEUTICAL INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.60%.
- ULTRAGENYX PHARMACEUTICAL INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -0.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -1.10% 10-K · filed 2026-02-18 | |
| 2023-12-31 | -0.30% 10-K · filed 2026-02-18 | |
| 2022-12-31 | -0.60% 10-K · filed 2025-02-19 | |
| 2021-12-31 | -0.80% 10-K · filed 2024-02-21 | |
| 2020-12-31 | -0.90% 10-K · filed 2023-02-17 | |
| 2019-12-31 | -0.40% 10-K · filed 2022-02-15 | |
| 2018-12-31 | -0.80% 10-K · filed 2021-02-12 | |
| 2014-12-31 | -1.20% 10-K · filed 2017-02-17 | 1.20% 10-K · filed 2015-03-27 |
| 2013-12-31 | 2.90% 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |